Dimitrios L. Wagner

🚨 Our work on optimizing single-stranded DNA donors with Cas12a binding moieties is published at @MolTherapy Nucleic Acids! Since the preprint, we added two super interesting findings. Short 🧵👇 (1/4) cell.com/molecular-ther…

The recent work from the lab on mKRAS peptide-specific CAR T cells is now available online. A pipeline of new peptide-centric CARs is now in process. Stay tuned. #CAR #KRAS Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy sciencedirect.com/science/articl…

🔬"Approaches to target solid tumors and the tumor microenvironment with adoptive T cell therapies." Thank you Katie McKenna Ph.D. @McKenna_PhD17 for sharing your work with us! What approaches have you found effective in targeting solid tumors?📝

🚨 A bold approach to treating severe autoimmunity: We explored CRISPR-Cas9 mediated deletion of the PR3 autoantigen in blood stem cells as a strategy for ANCA-associated vasculitis. 🧬 Great idea and execution by Kettritz lab @ChariteBerlin 🔗 doi.org/10.1016/j.kint…

Gene editing of CD3 epsilon to redirect regulatory T cells for adoptive T cell transfer: Molecular Therapy cell.com/molecular-ther… Great to see this collaboration now out in @MolTherapy @fgissa @olivermccallion @dlwagner13

Expanding the engineered Treg universe! A treat to write this Commentary @MolTherapy with Russell Cochrane and Eva Allen on T cell receptor fusion construct (TRuC) Tregs! 🛻 Congratulations @dlwagner13 on the exciting development! cell.com/molecular-ther… cell.com/molecular-ther…

🚨Excited to share our latest work, now out in @NatureBiotech ! We introduce SEED-Selection, a powerful method that enables high-efficiency enrichment of T cells edited at multiple loci in a single step 🧵👇 🔗 nature.com/articles/s4158…

1/ Pleased to share our review, published today @NatRevImmunol, highlighting how biomolecular condensates enhance the precision and flexibility of gene regulatory networks that guide fate decisions during normal and pathological immune cell development. nature.com/articles/s4157…

1/11 🚀My recent work from @sahakris lab describes a virus-free CRISPR method to engineer highly effective NK cells for solid tumor therapy. This approach targets the KLRC1 gene and has several updates from our earlier preprint. 🧵#CellTherapy #Immunotherapy #CancerResearch

🚀 Our allogeneic #CRISPR natural killer cell therapy is featured in @MolTherapy! 🌟 Dive into @Shankar_K2 brilliant insights below. Building on our groundbreaking nonviral CRISPR CAR T-cell work, this could revolutionize cancer treatment, including solid tumors!

SEED-Selection enables high-efficiency enrichment of primary T cells edited at multiple loci go.nature.com/4gBnaqY

🚨New paper alert! 🚨 Our latest work in @ImmunityCP shows that Ark313, an evolved AAV variant enables in vivo genetic engineering of murine T cells! 🧵👇 sciencedirect.com/science/articl…

Gene editing of CD3 epsilon gene to redirect regulatory T cells for adoptive T cell transfer cell.com/molecular-ther… @MolTherapy @dlwagner13

📢My UBC lab is recruiting two postdocs: (1) focus on topically applicable gene therapies to rescue severe skin diseases, (2) bioengineering of complex human-based models harnessing organ-on-a-chip technology: @UBC (1) lnkd.in/dvcGqWaE (2) lnkd.in/dmYCA74K

🚨New! 🚨 Our new paper is now out in @MedCellPress sciencedirect.com/science/articl… Discover how clinical Treg therapy shapes immune responses in transplants

Drs. Brenner, Rooney named National Academy of Inventors Fellows. @AcadofInventors @bcmhouston @BCMDeptMedicine @bcmgenetics @BCMCancerCenter @CAGTHouston bcm.edu/news/drs-brenn…

High affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells dlvr.it/TGRPj9 #MTMCD